Skip to main content
Equibles
HCWB logo

HCWB · HCW Biologics Inc.

Track HCWB — free

Use HCWB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.25 -0.11 (-3.13%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the date of issuance of the Company's condensed financial statements, without additional funding or financial support. After considering management's plan for financing and funds raised that are probable to occur within one year, as well as that the Company expects to continue to incur losses from operations for the foreseeable future, management concluded that the substantial doubt that existed in its going concern analysis as of June 30, 2026 was not alleviated.”
View the 10-Q filed Aug 14, 2026
Market Cap
$6.26M
Shares
1.84M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-04-20 Development of HCW11-018b (T Cell Engager), An Innovative Approach to Improve Bispecific T-Cell Engagers for Solid Tumor Therapy (Poster presented at AACR Annual Meeting 2026) Shareholder meeting
2025-11-07 A Debut of HCWB’s 2nd Gen T-cell Engager IND-Enabling Study Data - 40th SITC2025 Poster Event
2025-10-22 Video: Dr. Peter Rhode Participated in a Virtual Investor “What This Means” Segment About HCWB’s Second Generation Proprietary Immune Checkpoint Inhibitor Event
2025-09-30 Video: Dr. Peter Rhode Participated in a Virtual Investor “What This Means” Segment About HCWB’s Second Generation Proprietary T-Cell Engager Program Event
2025-06-27 2025 Annual Meeting – Replay Instructions Shareholder meeting
2023-11-05 38th Annual SITC Conference Conference
2023-04-19 HCW9218 Underlying Mechanism of Action Against Solid Tumors, AACR Annual Meeting 2023 Shareholder meeting
2022-11-14 A Phase 1 Study of HCW9218, a Bifunctional TGF-β Antagonist/IL-15 Protein Complex, in Advanced Solid Tumors, SITC Annual Meeting 2022 Shareholder meeting
2022-05-09 Robust human regulatory T cell expansion with fusion proteins HCW9302 and HCW9213 circumvents need for magnetic-bead or feeder cell approaches for adoptive cell therapy – Immunology 2022 Event
2022-05-09 A “kick and expand” strategy to generate large numbers of CIML NK cells for adoptive cell therapy for the treatment of cancer using novel fusion proteins HCW9201 and HCW9206 – Immunology 2022 Event

Source: https://investors.hcwbiologics.com/

Key facts CIK 1828673 CUSIP 40423R303 13F (30d) 11 filings 11 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)